Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor

@article{Abrams2009RivaroxabanAN,
  title={Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor},
  author={Paris Abrams and Christopher R. Emerson},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2009},
  volume={29}
}
Thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke often result in long‐term disability and/or mortality. The anticoagulants currently available have been effective in the treatment and prevention of these disorders; however, parenteral administration, variable pharmacokinetics and pharmacodynamics, drug and dietary interactions, and a requirement for frequent monitoring of efficacy and safety limit use of these drugs. Rivaroxaban is a… Expand
View on Wiley
ncbi.nlm.nih.gov
52 Citations
Highly Influential Citations
3
Background Citations
14
Methods Citations
1

52 Citations

Citation Type

Citation Type

Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
  • 5
  • PDF
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
  • 129
Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor.
  • 16
  • Highly Influenced
  • PDF
Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics
  • 19
  • PDF
Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs
  • 7
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice
  • 8
  • PDF
Novel oral anticoagulants for the prevention and treatment of thromboembolism.
  • 2
Emerging options in the treatment of deep vein thrombosis and pulmonary embolism.
  • 21
Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation
  • PDF
The role of novel anticoagulants in the management of venous thromboembolism
  • 7
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 66 REFERENCES
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases
  • A. Turpie
  • Medicine
  • Arteriosclerosis, thrombosis, and vascular biology
  • 2007
  • 205
  • PDF
Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases
  • 105
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
  • 45
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin
  • 175
New oral anticoagulants in atrial fibrillation.
  • 191
  • PDF
Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.
  • 152
  • PDF
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study
  • 332
  • Highly Influential
Effects of Renal Impairment on the Pharmacology of Rivaroxaban (BAY 59-7939) - An Oral, Direct, Factor Xa Inhibitor.
  • 23
The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor.
  • 78
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
  • 297
  • PDF
...
1
2
3
4
5
...